In the late 1990s, Procter & Gamble tested an unusual idea.
Instead of asking parents to apply barrier cream separately at every diaper change, its researchers placed skin-protective ingredients directly onto the diaper’s inner surface.
As the baby wore the diaper, a formulation containing zinc oxide and petrolatum transferred gradually from the topsheet to the skin.
The diaper was no longer only absorbing urine and containing waste.
It was also administering a protective skin treatment.
Clinical research published in 2001 reported that the formulation transferred successfully during wear and that children using the treated diapers experienced lower diaper-dermatitis severity than those using conventional diapers.
More than two decades later, Chinese diaper brands are presenting related ideas through a new vocabulary:
- • Camellia-oil-infused surfaces
- • Plant-extract skin barriers
- • Skincare diapers
- • Cream-like softness
- • Continuous soothing protection
The underlying mechanism is not entirely new.
What has changed is the way it is formulated, marketed and understood by parents.
This is one signal from the Consensys Innovation Signals Engine, which continuously scans a library of more than one million products worldwide for emerging shifts in formulation, positioning and consumer demand.
P&G treated the diaper as a delivery system
The research product used a diaper topsheet coated with a mixture of zinc oxide and petrolatum.
Both materials were already familiar in diaper-rash care.
Petrolatum forms an occlusive layer that helps reduce contact between the skin and moisture or irritants.
Zinc oxide is commonly used as a skin protectant in diaper-rash creams.
The technical leap was placing those ingredients on the diaper rather than asking the caregiver to apply them manually.
The published clinical programme included blinded, randomised studies designed to determine:
- • Whether the formulation transferred from the diaper to the skin
- • Whether transfer continued across repeated diaper changes
- • Whether the treated diapers were well tolerated
- • Whether they reduced the severity of diaper dermatitis
The investigators reported measurable transfer during both short and extended use and found lower overall dermatitis severity among children wearing the treated diapers.
The idea existed before the clinical paper
P&G’s work did not begin in 2000.
Patent records show that the company had been developing lotioned diaper topsheets during the 1990s.
A P&G patent filed in 1994 and granted in 1997 describes a diaper with an immobilised lotion composition on its liquid-permeable topsheet. During use, some of that lotion could transfer to the wearer’s skin and provide cleaning, protective or therapeutic benefits.
The patent addressed a practical manufacturing problem.
A lotion applied to a diaper cannot behave like ordinary cream in a jar. If it remains too fluid, it may:
- • Migrate into the absorbent core
- • Reduce urine acquisition
- • Transfer onto packaging
- • Become unevenly distributed
- • Lose effectiveness during storage
P&G therefore described a composition that remained substantially immobilised on the topsheet but softened and transferred through body contact during use.
The diaper acted almost like a slow-release patch, although it delivered a cosmetic barrier rather than a medicine.
This was not simply a laboratory prototype that disappeared
The original database row says P&G invented the technology and never shipped it.
That is too absolute.
P&G and other manufacturers have sold diapers with lotion-treated inner surfaces, and patents for such systems continued well beyond the original clinical research.
P&G’s 1997 patent explicitly described commercial diaper construction, manufacturing methods and lotion quantities. Later patents expanded on absorbent products intended to maintain or improve skin health.
Modern Pampers products have also used topsheet lotions or skin-protecting formulations in selected ranges and markets.
The narrower historical mystery is more interesting:
Why did the specific zinc-oxide-and-petrolatum system documented in the clinical research not become the defining global diaper format?
The public record confirms the technology and the clinical programme.
It does not establish P&G’s internal commercial decision.
A clinically effective idea can still be commercially difficult
Several factors may have limited wider adoption.
Cost
Applying a controlled skin-care formulation adds ingredients, equipment and quality-control steps to every diaper.
Absorption interference
A barrier ingredient that protects the skin may also make parts of the topsheet less receptive to liquid if applied too heavily.
Formula stability
The lotion must remain evenly distributed through manufacturing, shipping and storage.
Consumer concern
Some parents may prefer fewer ingredients in direct contact with an infant’s skin.
Regulatory and claim complexity
A diaper described as preventing or treating rash may face more scrutiny than one making general comfort claims.
Existing habits
Parents already understood how to purchase and apply separate diaper cream.
The technology had to outperform a cheap, familiar two-product routine:
ordinary diaper plus barrier cream.
The clinical formulation was closer to medicine than moisturising language
The historical P&G research used ingredients associated directly with barrier protection.
The modern Chinese market often communicates the concept differently.
Instead of leading with pharmaceutical-style ingredients such as zinc oxide and petrolatum, products may emphasise:
- • Camellia seed oil
- • Botanical extracts
- • Vitamin E
- • Softening ingredients
- • Sensitive-skin positioning
- • “Natural” protective layers
This shifts the idea from rash management toward premium daily skincare.
The diaper is no longer presented as treating a skin problem.
It is presented as maintaining soft, calm and comfortable skin throughout the day.
Babycare’s product uses camellia rather than the original barrier formula
Public listings for Babycare’s Camellia diaper range describe the addition of camellia seed oil or golden-camellia extract to the skin-facing system.
The company and retailers position the ingredient around softness, soothing and support for the infant skin barrier. The range has been commercially available since approximately 2021.
This is related to P&G’s older concept at the platform level:
A skin-benefit ingredient is incorporated into the surface that touches the baby.
But it is not the same formulation.
The P&G clinical system used zinc oxide and petrolatum with direct barrier-care intent.
Babycare’s published marketing emphasises camellia-derived skincare, softness and soothing.
The “commercial first” claim cannot be supported
The claim that Babycare introduced the first commercially available cream-infused diaper is contradicted by the historical patent and product record.
P&G had patented lotioned diapers in the 1990s. Other companies also developed absorbent products with lotions, emollients and skin-care treatments on their body-facing surfaces.
Even earlier, a 1969 US patent described a disposable-diaper topsheet treated with liquid petrolatum as a moisture-barrier material.
Babycare can more defensibly be described as:
- • A prominent Chinese commercial example
- • A premium botanical interpretation
- • An example of skincare language entering diaper design
- • A modern revival of skin-benefit topsheet technology
It should not be labelled the first without much stronger product-history evidence.
Why the idea feels new even when it is not
Parents rarely read diaper patents or clinical journals.
They encounter innovation through packaging, social media and retail claims.
A concept can therefore feel entirely new when three things change:
The ingredient story changes
“Camellia skincare” sounds newer and more premium than “petrolatum-coated topsheet.”
The category language changes
The product becomes a skincare diaper, not merely a diaper containing lotion.
The market changes
Chinese parents increasingly evaluate diapers through softness, sensitive-skin claims, botanical ingredients and premium material stories.
The underlying engineering may be decades old while the consumer proposition is newly relevant.
Babycare combined the treatment with a larger premium system
The Camellia proposition does not stand alone.
Babycare’s premium diaper range also emphasises:
- • Extremely fine surface fibres
- • Reduced friction
- • High breathability
- • Rapid fluid acquisition
- • Low rewet
- • Flexible waist and leg structures
- • Sensitive-skin testing
A detailed Chinese product review describes a 0.6-denier fibre surface, camellia-derived ingredients and a biomimetic absorbent core as parts of one combined skin-comfort platform. These are brand or retailer claims rather than independently established clinical outcomes.
This matters because diaper rash is not caused by one factor.
It can be influenced by:
- • Moisture
- • Friction
- • Urine and faecal irritants
- • Extended wear
- • Skin pH
- • Microbial activity
- • Individual sensitivity
A useful skin-protection diaper therefore needs more than a fashionable extract.
It must manage the complete environment against the skin.
Ingredient presence does not prove ingredient delivery
A major evidence question remains unanswered.
If a diaper contains camellia oil or another skin-care ingredient:
- • How much is applied?
- • Where is it located?
- • How much transfers to the skin?
- • How long does it remain?
- • Does urine remove it?
- • Does it affect absorption?
- • Does it reduce clinically assessed dermatitis?
- • Is the result different from an untreated diaper?
P&G’s historical studies measured transfer and clinical dermatitis severity.
Public Babycare materials reviewed for this article primarily provide product claims and safety-testing language, not an equivalent peer-reviewed clinical trial comparing the treated diaper with a control.
The modern product may be commercially sophisticated while having less publicly accessible clinical evidence than the older prototype.
“Natural barrier” is not the same as proven barrier protection
Botanical ingredients can contribute to a compelling consumer story.
But words such as natural, soothing and skin barrier can imply more than the available evidence demonstrates.
The clinical performance of a treated diaper depends on:
- • Ingredient concentration
- • Chemical stability
- • Transfer rate
- • Contact time
- • Interaction with moisture
- • Product construction
- • Individual skin response
A tiny amount of botanical extract included mainly for positioning may not perform like a conventional zinc-oxide barrier cream.
The product should be judged by demonstrated skin outcomes, not merely the familiarity or prestige of the ingredient.
Integrating cream into the diaper solves a genuine caregiver problem
Despite the evidence questions, the user need is real.
Applying conventional diaper cream can be:
- • Messy
- • Easy to forget
- • Inconsistent between caregivers
- • Difficult during nighttime changes
- • Inconvenient outside the home
A treated topsheet can provide more consistent exposure without an extra step.
This is particularly attractive in:
- • Day-care settings
- • Hospitals
- • Travel
- • Overnight use
- • Households with several caregivers
The product converts an optional caregiver action into a built-in feature.
But built-in delivery removes caregiver control
The same automation creates a disadvantage.
With separate cream, a parent can choose:
- • Which product to use
- • How much to apply
- • When to stop
- • Whether to use it only during irritation
- • Whether an ingredient suits the child
With an infused diaper, exposure occurs during every wear.
That raises questions involving:
- • Allergies
- • Fragrance
- • Sensitisation
- • Ingredient transparency
- • Accumulated exposure
- • Compatibility with prescribed treatment
The strongest products will disclose the complete formulation and allow parents to choose an untreated version easily.
The next generation could become genuinely personalised
The old P&G system and the newer Babycare approach suggest a larger innovation platform.
Future diapers could use targeted surface treatments designed around specific needs:
- • Friction reduction
- • Zinc-based barrier support
- • pH management
- • Preterm-infant skin
- • Faecal-enzyme inhibition
- • Sensitive-skin care
- • Overnight protection
However, claims involving treatment or disease prevention would require careful clinical and regulatory substantiation.
The technology could evolve from one universal lotion into controlled, evidence-based skin environments.
The bigger lesson is how inventions disappear and return
Consumer-product innovation is rarely a straight line.
A company may prove that a technology works yet fail to build the category around it.
Years later, another company can revive a related mechanism under new conditions:
- • Different ingredients
- • Different consumer expectations
- • Better manufacturing
- • Stronger premiumisation
- • More effective marketing language
- • A market more willing to pay
That appears to be what happened here.
P&G’s researchers treated the diaper as a continuous skin-care delivery system decades ago.
Modern Chinese brands have made the same general concept culturally and commercially visible through botanical skincare.
The invention did not wait 25 years to exist.
It waited for the market to understand it differently.
Brand Radar Signal Tags
Brands and Organisations
Procter & Gamble P&G Pampers Babycare Bc Babycare
Products and Platforms
P&G Zinc-Oxide/Petrolatum Experimental Diaper Lotioned Diaper Topsheet Babycare Golden Camellia Diapers Babycare Camellia Soft Diapers
Innovation Types
Continuous Topical Delivery Lotioned Topsheet Contact-Activated Lotion Transfer Botanical Skin-Care Diaper Skin-Benefit Surface Treatment Automatic Barrier-Care Delivery Multi-Mechanism Skin Protection Condition-Specific Diaper Surface Innovation Revival Therapeutic-to-Premium Reframing
Ingredients and Technologies
Zinc Oxide Petrolatum Camellia Seed Oil Golden Camellia Extract Vitamin E Immobilised Lotion Body-Heat Transfer Skin-Facing Topsheet Ultra-Fine Surface Fibre
Consumer Benefits
Reduced Manual Cream Application Continuous Skin Protection Reduced Friction Sensitive-Skin Support Caregiver Convenience Consistent Application Night-Time Skin Care
Market Signals
Skincare-Diaper Convergence Premium Chinese Diaper Innovation Botanical Ingredient Premiumisation Rediscovered R&D Innovation Through Reframing Beauty Language Entering Baby Care Patented Technology Revival
Evidence Signals
Randomised Blinded Clinical Research Demonstrated Lotion Transfer Reduced Dermatitis Severity P&G Patent Evidence Public Babycare Clinical Evidence Limited Commercial-First Claim Unsupported Product-Specific Transfer Data Needed Brand Claims Require Independent Validation
Risk Signals
Ingredient Halo Continuous Unchosen Exposure Possible Absorption Interference Formula Migration Allergy and Sensitisation Risk Therapeutic Claim Regulation Botanical Claim Overstatement
Sources
Historical clinical research
- • Baldwin et al. — “Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper”: Randomised blinded studies assessed ingredient transfer and diaper-dermatitis severity. https://pubmed.ncbi.nlm.nih.gov/11720074/
- • Review of diaper dermatitis and diaper technology: Discusses the Odio and Baldwin research programme and transfer of lotion from treated topsheets to infant skin.
P&G patent history
- • US5643588A — Diaper having a lotioned topsheet: P&G patent describing an immobilised lotion that transfers during wear to provide protective, therapeutic or cleaning benefits. https://patents.google.com/patent/US5643588A/en
- • US6627787B1 — Diaper having a lotioned topsheet: Continued P&G patent family covering lotioned absorbent products. https://patents.google.com/patent/US6627787B1/en
- • Earlier petrolatum-treated topsheet patent: A 1969 patent demonstrates that moisture-barrier treatment of diaper topsheets predates both the P&G clinical research and Babycare. https://patents.google.com/patent/US3489148A/en
Babycare product evidence
- • Babycare official site: Current diaper portfolio and company positioning. https://www.babycare.com/
- • Babycare Camellia diaper retail listing: Identifies added camellia seed oil in the diaper range.
- • Babycare Golden Camellia product overview: Describes the range’s launch history, fine-fibre topsheet, camellia extract and skin-barrier claims. These should be treated as commercial product claims rather than independent clinical evidence.